Market Overview:
The global congestive heart failure (CHF) market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of CHF, rising geriatric population, and technological advancements in the treatment of CHF. The global congestive heart failure (CHF) market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into injection, capsule, and tablets. The injection segment is expected to grow at a CAGR of 6% from 2018 to 2030 due to its high adoption rate among patients owing to its ease-of-use and fast action time. On the basis of application, the market is divided into hospital and clinic settings. The hospital setting segment dominates this market with a share of more than 60%.
 Industry Outlook.svg)
Product Definition:
Congestive heart failure (CHF) is a condition in which the heart can't pump enough blood to meet the body's needs.
Injection:
Injection is a medication used to treat congestive heart failure (CHF) and pulmonary hypertension. The medicine works by opening up the blood vessels that are constricted due to which the flow of blood in the body decreases, thereby increasing the oxygen level in the blood. In cases where there is insufficient oxygen supply to tissues, injections can be life-saving as they increase tissue oxygenation by improving cardiac output.
Capsule:
The capsule is a small, plastic device that contains medicine or drug and it works by releasing the contents inside the body. It can be used in various conditions such as heart failure, angina (chest pain), hypertension, and others. The main function of this device is to increase blood flow by opening the blood vessels so that more oxygenated blood can reach to the tissue and organs which need it most.
Application Insights:
Based on application, the market is segmented into hospital-based and clinic-based. Hospital-based clinics accounted for the largest share in 2017 owing to a high prevalence of CHF patients at hospitals. Moreover, an increase in the number of hospitals offering Congestive Heart Failure (CHF) treatment has also positively influenced segment growth. For instance, as per National Health Profile 2015, there were more than 400 hospitals providing chronic heart failure services in India which was a rise from previous year's figure of 300+. This factor is anticipated to drive demand over next few years.
Clinic-based segments are expected to witness significant growth during forecast period due largely to increasing awareness about CHF among general population coupled with availability of advanced treatments such as cardiac rehabilitation centers and home healthcare services for treating this condition.
Regional Analysis:
North America dominated the global market in 2017. High awareness levels regarding congestive heart failure, favorable reimbursement policies, and availability of highly skilled physicians are some of the major factors responsible for its large share. Moreover, an increase in healthcare expenditure and rise in patient awareness levels about their treatment options are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to a large population base with high unmet medical needs coupled with rapidly improving healthcare infrastructure and rising disposable income especially in developing countries such as China & India will boost demand for CHF drugs over the coming years. Furthermore, increasing cases of obesity have been identified as one ofthe key risks factor associated with CHF which if not treated can lead to serious health consequences such as right-sided heart failure or cardiac arrest which can further escalate costs involved into tens or hundreds of thousands dollars per year making it inaccessible for most people suffering from this condition thus hampering market growth significantly.
Growth Factors:
- Increasing prevalence of CHF due to aging population and rising incidence of cardiovascular diseases.
- Growing demand for novel therapeutics for the treatment of CHF.
- increasing number of clinical trials for the development of new drugs for the treatment of CHF.
Scope Of The Report
Report Attributes
Report Details
Report Title
Congestive Heart Failure (CHF) Market Research Report
By Type
Injection, Capsule, Tablets
By Application
Hospital, Clinic
By Companies
Sanofi, Novartis, Pfizer, Merck & Co, AstraZeneca, GSK, Bristol-Myers Squibb, Mylan, Bausch Health, Johnson & Johnson, Bayer, Boehringer Inhelheim, Exelixis, Lunan Pharmaceutical, Sinepharm, CRC, Hai Ni Pharmaceutical, Langtian, NCPC, Hayao, Xinhua Group, Xudong Haipu Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
160
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Congestive Heart Failure (CHF) Market Report Segments:
The global Congestive Heart Failure (CHF) market is segmented on the basis of:
Types
Injection, Capsule, Tablets
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Novartis
- Pfizer
- Merck & Co
- AstraZeneca
- GSK
- Bristol-Myers Squibb
- Mylan
- Bausch Health
- Johnson & Johnson
- Bayer
- Boehringer Inhelheim
- Exelixis
- Lunan Pharmaceutical
- Sinepharm
- CRC
- Hai Ni Pharmaceutical
- Langtian
- NCPC
- Hayao
- Xinhua Group
- Xudong Haipu Pharmaceutical
 Market Overview.svg)
Highlights of The Congestive Heart Failure (CHF) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Capsule
- Tablets
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Congestive Heart Failure (CHF) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Congestive heart failure (CHF) is a condition in which the heart cannot pump enough blood to meet the body's needs. CHF can cause shortness of breath, fatigue, and chest pain. It can lead to death if not treated.
Some of the key players operating in the congestive heart failure (chf) market are Sanofi, Novartis, Pfizer, Merck & Co, AstraZeneca, GSK, Bristol-Myers Squibb, Mylan, Bausch Health, Johnson & Johnson, Bayer, Boehringer Inhelheim, Exelixis, Lunan Pharmaceutical, Sinepharm, CRC, Hai Ni Pharmaceutical, Langtian, NCPC, Hayao, Xinhua Group, Xudong Haipu Pharmaceutical.
The congestive heart failure (chf) market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Congestive Heart Failure (CHF) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Congestive Heart Failure (CHF) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Congestive Heart Failure (CHF) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Congestive Heart Failure (CHF) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Congestive Heart Failure (CHF) Market Size & Forecast, 2018-2028
4.5.1 Congestive Heart Failure (CHF) Market Size and Y-o-Y Growth
4.5.2 Congestive Heart Failure (CHF) Market Absolute $ Opportunity
Chapter 5 Global Congestive Heart Failure (CHF) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Congestive Heart Failure (CHF) Market Size Forecast by Type
5.2.1 Injection
5.2.2 Capsule
5.2.3 Tablets
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Congestive Heart Failure (CHF) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Congestive Heart Failure (CHF) Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Congestive Heart Failure (CHF) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Congestive Heart Failure (CHF) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Congestive Heart Failure (CHF) Analysis and Forecast
9.1 Introduction
9.2 North America Congestive Heart Failure (CHF) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Congestive Heart Failure (CHF) Market Size Forecast by Type
9.6.1 Injection
9.6.2 Capsule
9.6.3 Tablets
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Congestive Heart Failure (CHF) Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Congestive Heart Failure (CHF) Analysis and Forecast
10.1 Introduction
10.2 Europe Congestive Heart Failure (CHF) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Congestive Heart Failure (CHF) Market Size Forecast by Type
10.6.1 Injection
10.6.2 Capsule
10.6.3 Tablets
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Congestive Heart Failure (CHF) Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Congestive Heart Failure (CHF) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Congestive Heart Failure (CHF) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Congestive Heart Failure (CHF) Market Size Forecast by Type
11.6.1 Injection
11.6.2 Capsule
11.6.3 Tablets
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Congestive Heart Failure (CHF) Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Congestive Heart Failure (CHF) Analysis and Forecast
12.1 Introduction
12.2 Latin America Congestive Heart Failure (CHF) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Congestive Heart Failure (CHF) Market Size Forecast by Type
12.6.1 Injection
12.6.2 Capsule
12.6.3 Tablets
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Congestive Heart Failure (CHF) Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Congestive Heart Failure (CHF) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Congestive Heart Failure (CHF) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Congestive Heart Failure (CHF) Market Size Forecast by Type
13.6.1 Injection
13.6.2 Capsule
13.6.3 Tablets
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Congestive Heart Failure (CHF) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Congestive Heart Failure (CHF) Market: Competitive Dashboard
14.2 Global Congestive Heart Failure (CHF) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Novartis
14.3.3 Pfizer
14.3.4 Merck & Co
14.3.5 AstraZeneca
14.3.6 GSK
14.3.7 Bristol-Myers Squibb
14.3.8 Mylan
14.3.9 Bausch Health
14.3.10 Johnson & Johnson
14.3.11 Bayer
14.3.12 Boehringer Inhelheim
14.3.13 Exelixis
14.3.14 Lunan Pharmaceutical
14.3.15 Sinepharm
14.3.16 CRC
14.3.17 Hai Ni Pharmaceutical
14.3.18 Langtian
14.3.19 NCPC
14.3.20 Hayao
14.3.21 Xinhua Group
14.3.22 Xudong Haipu Pharmaceutical
